Site icon OncologyTube

ASCO Lung Cancer Roundtable – NSCLC – The CITYSCAPE Trial: Anti TIGIT & Immune Checkpoint Inhibitor

We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.

Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is Trial Updates – Anti-TIGIT and NSCLC PDL1, and the CITYSCAPE Trial – Adding Tiragolumab (Anti-TIGIT) to an Immune Checkpoint Inhibitor – A Better Treatment Option?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Advertisement
Exit mobile version